In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone

JE Leysen, PM Janssen, W Gommeren, J Wynants, PJ Pauwels and PA Janssen

Department of Biochemical Pharmacology, Janssen Research Foundation, Beerse, Belgium.

Risperidone and ocaperidone are new benzisoxazol antipsychotics with particularly beneficial effects in schizophrenia. We report a comprehensive study on the in vitro and in vivo receptor binding profile of the new compounds, compared with haloperidol, and on the drug effects on monoamine and metabolite levels in various brain areas. The in vitro receptor binding and monoamine uptake inhibition profiles, comprising 29 receptors and four monoamine uptake systems, revealed that ocaperidone and risperidone bound primarily, and with the highest affinity thus far reported, to serotonin 5HT2 receptors (Ki values of 0.14 and 0.12 nM, respectively). Further, the drugs bound at nanomolar concentrations to the following receptors (Ki values, in nM, for ocaperidone and risperidone, respectively): alpha 1-adrenergic (0.46 and 0.81), dopamine D2 (0.75 and 3.0), histamine H1 (1.6 and 2.1), and alpha 2-adrenergic (5.4 and 7.3). In contrast, haloperidol showed nanomolar affinity for D2 receptors (1.55) and haloperidol-sensitive sigma sites (0.84) only. The in vitro binding affinity of ocaperidone, risperidone, and haloperidol for D2 receptors was exactly the same when measured in membranes from rat striatum, nucleus accumbens, tuberculum olfactorium, and human kidney cells expressing the cloned human D2 receptor (long form). In vivo binding in rats, using intravenous administration of [3H]spiperone, revealed very potent occupation by ocaperidone and risperidone of 5HT2 receptors in the frontal cortex (ED50 of 0.04-0.03 mg/kg); in this respect, they were 6, 30, and 100 times more potent than ritanserin, haloperidol, and clozapine, respectively. Ocaperidone occupied D2 receptors in the striatum and the nucleus accumbens with similar potency as did haloperidol (ED50 of 0.14- 0.16 mg/kg). Risperidone revealed biphasic inhibition curves in the latter brain areas, indicating that [3H] spiperone labeled both 5HT2 receptors (occupied by risperidone at less than 0.04 mg/kg) and D2 receptors (risperidone ED50 of approximately 1 mg/kg). In the tuberculum olfactorium, 5HT2 and D2 receptors were also distinguished with risperidone. The ED50 values for occupation of the latter were for ocaperidone and risperidone 2 times lower and for haloperidol 2 times higher than in the striatum. Ocaperidone, risperidone, and haloperidol readily increased the levels of the dopamine metabolites 3,4- dihydroxybenzene acetic acid and homovanillic acid in the striatum, the nucleus accumbens, the tuberculum olfactorium, and, to some extent, the frontal cortex. Dose-response curve shapes were markedly different; with ocaperidone maximal levels were reached at 0.16 mg/kg and maintained to 10 mg/kg; with risperidone the levels tended to increase continuously up to 10 mg/kg. Haloperidol produced dome-shaped curves (maximum at 0.16-0.63 mg/kg).(ABSTRACT TRUNCATED AT 400 WORDS)

Volume 41, Issue 3, pp. 494-508, 03/01/1992
Copyright © 1992 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				L. C. Parr-Brownlie and B. I. Hyland Bradykinesia Induced by Dopamine D2 Receptor Blockade Is Associated with Reduced Motor Cortex Activity in the Rat J. Neurosci., June 15, 2005; 25(24): 5700 - 5709. [Abstract] [Full Text] [PDF]

				R. Knegtering, P. Baselmans, S. Castelein, F. Bosker, R. Bruggeman, and R. J. van den Bosch Predominant Role of the 9-Hydroxy Metabolite of Risperidone in Elevating Blood Prolactin Levels Am J Psychiatry, May 1, 2005; 162(5): 1010 - 1012. [Abstract] [Full Text] [PDF]

				R. Brys, K. Josson, M. P. Castelli, M. Jurzak, P. Lijnen, W. Gommeren, and J. E. Leysen Reconstitution of the Human 5-HT1D Receptor-G-Protein Coupling: Evidence for Constitutive Activity and Multiple Receptor Conformations Mol. Pharmacol., June 1, 2000; 57(6): 1132 - 1141. [Abstract] [Full Text]

				H. TAKAHASHI Acute Dystonia Induced by Adding Midodrine, a Selective Alpha 1 Agonist, to Risperidone in a Patient With Catatonic Schizophrenia J Neuropsychiatry Clin Neurosci, May 1, 2000; 12(2): 285 - 286. [Full Text] [PDF]

				M. M. Robertson Tourette syndrome, associated conditions and the complexities of treatment Brain, March 1, 2000; 123(3): 425 - 462. [Abstract] [Full Text] [PDF]

				R. G. Johnson, K. E. Stevens, and G. M. Rose 5-Hydroxytryptamine2 Receptors Modulate Auditory Filtering in the Rat J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 643 - 650. [Abstract] [Full Text]

				A. Fink-Jensen, L. Hansen, J. B. Hansen, and E. B. Nielsen Regional differences in the effect of haloperidol and atypical neuroleptics on interstitial levels of DOPAC in the rat forebrain: an in vivo microdialysis study J Psychopharmacol, January 1, 1996; 10(2): 119 - 125. [Abstract] [PDF]

				M. M. Robertson, D. A. Scull, V. Eapen, and M. R. Trimble Risperidone in the treatment of Tourette syndrome: a retrospective case note study J Psychopharmacol, January 1, 1996; 10(4): 317 - 320. [Abstract] [PDF]

				J G Edwards Risperidone for schizophrenia BMJ, May 21, 1994; 308(6940): 1311 - 2. [Full Text]